McCarthy, Mark I.
Article History
First Online: 4 January 2017
Competing interests
: M.I.McC. is a member of Advisory Boards at NovoNordisk and Pfizer. He has received honoraria from EliLilly, NovoNordisk and Pfizer, and research funding (via the Innovative Medicines Initiative and the Accelerating Medicines Partnership) from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi-Aventis, Servier and Takeda.